Cardiol Historical Cash Flow
| CRDL Stock | CAD 2.26 0.05 2.16% |
Analysis of Cardiol Therapeutics cash flow over time is an excellent tool to project Cardiol Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 4 K or Begin Period Cash Flow of 62.4 M as it is a great indicator of Cardiol Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cardiol Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cardiol Therapeutics is a good buy for the upcoming year.
Cardiol |
About Cardiol Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cardiol balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cardiol's non-liquid assets can be easily converted into cash.
Cardiol Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Capital Expenditures
Capital Expenditures are funds used by Cardiol Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cardiol Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Cardiol Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Cardiol Therapeutics' Begin Period Cash Flow is very stable compared to the past year. As of the 2nd of December 2024, Other Non Cash Items is likely to grow to about 5.1 M, while Sale Purchase Of Stock is likely to drop 0.00.
Cardiol Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Cardiol Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiol Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 142.6K | 1.1M | 18.0K | (4.5M) | (5.1M) | (4.9M) | |
| Investments | (424.3K) | (40.6K) | (12.9K) | (74.7K) | (101.4K) | (106.5K) | |
| Change In Cash | (9.8M) | 7.1M | 69.9M | (24.4M) | (24.5M) | (23.3M) | |
| Net Borrowings | (20.2K) | (50.5K) | (51.9K) | (53.9K) | (48.5K) | (46.1K) | |
| Stock Based Compensation | 3.3M | 2.8M | 8.5M | 5.0M | 4.2K | 4.0K | |
| Free Cash Flow | (11.8M) | (9.2M) | (23.6M) | (27.3M) | (25.2M) | (24.0M) | |
| Change In Working Capital | (1.6M) | 8.3M | 76.5K | 5.7M | (545.9K) | (518.6K) | |
| Begin Period Cash Flow | 16.7M | 7.0M | 14.0M | 83.9M | 59.4M | 62.4M | |
| Total Cashflows From Investing Activities | (424.3K) | (40.6K) | (12.9K) | (74.7K) | (85.9K) | (90.2K) | |
| Other Cashflows From Financing Activities | 382.2K | (904.5K) | 9.4M | (53.93) | (64.3K) | (61.1K) | |
| Depreciation | 150.6K | 229.5K | 220.4K | 219.9K | 248.4K | 190.7K | |
| Other Non Cash Items | 507.7K | 145.0K | 4.2M | (7.3M) | 4.8M | 5.1M | |
| Capital Expenditures | 424.3K | 40.6K | 12.9K | 74.7K | 64.3K | 75.4K | |
| Total Cash From Operating Activities | (11.4M) | (9.2M) | (23.6M) | (27.2M) | (25.2M) | (23.9M) | |
| Change To Account Receivables | (467.1K) | 707.9K | (59.9K) | (144.2K) | 200.3K | 210.3K | |
| Change To Operating Activities | 227.6K | (64.1K) | (2.3M) | 1.4M | 1.6M | 1.7M | |
| Net Income | (13.7M) | (20.6M) | (31.6M) | (30.9M) | (28.1M) | (29.5M) | |
| Total Cash From Financing Activities | 2.0M | 16.3M | 93.4M | (53.9K) | (55.4K) | (52.6K) | |
| End Period Cash Flow | 7.0M | 14.0M | 83.9M | 59.5M | 34.9M | 34.3M | |
| Change To Netincome | 3.8M | 2.9M | 7.8M | (2.3M) | (2.0M) | (1.9M) | |
| Change To Liabilities | (1.5M) | 1.8M | 2.4M | 4.5M | 5.1M | 5.4M | |
| Issuance Of Capital Stock | 1.7M | 17.3M | 84.1M | 62.1M | 71.4M | 39.4M |
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardiol Stock
Moving against Cardiol Stock
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.